Filing Flows › Neuroone Medical Technologies (NMTC) › Q3 FY25
Neuroone Medical Technologies (NMTC) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Aug 14, 2025
Neuroone Medical Technologies (NMTC) reported revenue of $1.7M for the third quarter fiscal 2025 (Q3 FY25), +105% from a year earlier and +22% from the quarter before. Operating margin was -111.2%, net loss $1.5M (88.5% of revenue).
Neuroone Medical Technologies, Q3 FY25: revenue $1.7M (+105% year over year), operating margin -111.2%, net loss $1.5M, operating cash flow −$1.5M. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.7M | +22% | +105% |
| Operating profit | −$1.9M | — | — |
| Net earnings | −$1.5M | — | — |
| Operating cash flow | −$1.5M | — | — |
What changed
Revenue was $1.7M in Q3 FY25, up 105% year over year and up 22% from the previous quarter.
Gross margin was 53.9%, up 19.8 points from a year earlier. Operating costs exceeded revenue by $1.9M, an operating margin of -111.2%. Operating expenses fell 9% while revenue rose 105%. The quarter ended with a net loss of $1.5M, narrower than the previous quarter's $2.3M loss. Non-operating items added $386K, -26% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$1.5M. Non-cash charges added back $67K of depreciation and amortization and $317K of share-based compensation. Working capital and other items used $346K. Capital expenditures of $44K exceeded it, leaving free cash flow of −$1.5M.
Questions
What was Neuroone Medical Technologies' revenue in the third quarter fiscal 2025?
Neuroone Medical Technologies (NMTC) reported revenue of $1.7M for the third quarter fiscal 2025 (Q3 FY25), +105% from a year earlier and +22% from the quarter before.
Was Neuroone Medical Technologies profitable in the third quarter fiscal 2025?
Operating loss was $1.9M (-111.2% of revenue) and net loss $1.5M.